What the FDA labels say about taking them together
Atazanavir and sofosbuvir/velpatasvir/voxilaprevir
Atazanavir's FDA label of August 6, 2025 names sofosbuvir/velpatasvir/voxilaprevir in its drug interactions section, and sofosbuvir/velpatasvir/voxilaprevir's label names atazanavir too. The sofosbuvir/velpatasvir/voxilaprevir label: “Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the atazanavir label say about sofosbuvir/velpatasvir/voxilaprevir?
Atazanavir label, drug interactionsHepatitis C Antiviral Agents elbasvir/grazoprevir ↑ grazoprevir Coadministration of atazanavir with grazoprevir is contraindicated due to the potential for increased risk of ALT elevations [see Contraindications (4) ]. glecaprevir/pibrentasvir ↑ glecaprevir ↑ pibrentasvir Coadministration of atazanavir with glecaprevir/pibrentasvir is contraindicated due to the potential for increased the risk of ALT elevations [see Contraindications (4) ]. voxilaprevir/sofosbuvir/velpatasvir ↑ voxilaprevir Coadministration with atazanavir is not recommended.
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about atazanavir?
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsConcomitant Drug Class/Drug Name: atazanavir lopinavir; Effect on Concentration ↓ = decrease, ↑ = increase.: ↑ voxilaprevir; Clinical Effect/Recommendation: Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended.
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | HIV | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once